Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

June
30
2026

How 2026 Code Changes Shifted SRT from Sensus Healthcare to a Standard Treatment Option

For nearly a century, surgical excision and Mohs surgery have been the gold standard for treating patients who have non-melanoma skin cancer (NMSC) and keloid disease. The surgery works extremely well – with cure rates…

January
03
2020

85.6% Cure Rate for Keloids Treated by SRT Post Surgery

Those who suffer from keloid scarring are often left wondering what they can do to finally get rid of their keloids for good. Superficial Radio Therapy is quickly becoming a popular solution to treat keloids…

December
27
2019

Battling Skin Cancer? Look No Further than the Non-Surgical SRT-100™ for Your Squamous Cell Carcinoma Treatment

Squamous cell carcinoma is the second most common type of skin cancer. There are more than 700,000 new cases diagnosed each year in the United States. Fortunately, there is a new Squamous Cell Carcinoma Treatment…

December
18
2019

SRT-100™: Cure Your Patients with This Revolutionary Non-Surgical Squamous Cell Carcinoma Treatment

Each year, there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostate and colon. Nearly four million people in the United States will be diagnosed with basal…

August
23
2019

SRT is a Great Alternative for Treating Non Melanoma Skin Cancer vs using Mohs Surgery

NMSC includes Basal Cell Carcinoma and Squamous Cell Carcinoma. These cancers are rarely life-threatening but can cause complications if they are left untreated. Many dermatologists default to Mohs Surgery for the treatment of these malignancies….

Archives
Archives

IN THE NEWS

From Scalpel to SRT: Impact of Innovation on the Dermatology Industry